Menopur

Menotrophin, the active ingredient in Menopur, is a gonadotropin (FSH/LH) presented as an injectable solution for intramuscular or subcutaneous use. It provides exogenous FSH and LH activity to stimulate follicular development and ovulation in women and to support spermatogenesis in men with specific infertility conditions.

GNH USA supplies Menopur as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products, including regulatory support for import and export.

Menopur, a gonadotropin used in reproductive medicine, is indicated for several infertility‑related conditions.

Infertility due to anovulation: promotes follicular growth to enable ovulation in women who do not ovulate spontaneously. Controlled ovarian stimulation for IVF/ICSI: supports multiple follicle development to retrieve oocytes for assisted reproductive technologies. Induction of ovulation in hypogonadotropic hypogonadism: replaces deficient gonadotropins to trigger ovulation in women with low endogenous FSH/LH. Stimulation of spermatogenesis in hypogonadotropic hypogonadism: provides LH and FSH activity to encourage sperm production in affected men.

Menopur may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Abdominal discomfort or bloating - Injection site pain or erythema - Mild ovarian hyperstimulation symptoms such as mild abdominal pain - Headache or nausea

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (severe) leading to fluid accumulation and organ dysfunction - Multiple pregnancy (twins or higher order) - Thromboembolic events or severe allergic reactions including anaphylaxis

When prescribing Menopur, clinicians should observe the following precautions.

Monitor ovarian response: use ultrasound and estradiol measurements to adjust dosing and reduce risk of hyperstimulation. Avoid use in pregnancy: Menopur is not indicated for treatment during pregnancy and should be discontinued if pregnancy occurs. Assess for hypersensitivity: discontinue immediately if signs of allergic reaction such as rash, itching, or swelling appear. Consider risk of multiple gestation: counsel patients about the increased chance of twins or higher-order pregnancies. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications; notable interactions are categorized by clinical significance.

Major Interactions (Avoid): - GnRH agonists: may amplify ovarian response and increase risk of severe hyperstimulation. - Hormonal contraceptives: can blunt the intended ovulatory effect of Menopur. - Anticoagulants: heightened risk of bleeding if severe ovarian hyperstimulation occurs.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: may alter the hormonal milieu and affect response. - Corticosteroids: can influence endogenous hormone levels and modify treatment outcomes.